Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

The Georgetown test has been administered to more patients than Lympro. If new numbers for lympro come out of a multivariate analysis, then they would have to be verified.

The last study of Lympro had somewhere around 150, with half of the people being normal.

The last study on amyloid had 9500.

I am not saying that the comb of Lympro and the Georgetown test would be bad. I think that IS the way to go, or at least study it, but that has not been done yet.

Once again, GC is talking about things as if they are finished when they have not started yet.

I remember folks getting emails saying that the July data would be fine, and then having things go haywire. That was just 10 months ago.